Last reviewed · How we verify
hepatitis B vaccines — Competitive Intelligence Brief
phase 3
Biologic
Live · refreshed every 30 min
Target snapshot
hepatitis B vaccines (hepatitis B vaccines) — National Heart, Lung, and Blood Institute (NHLBI). Stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| hepatitis B vaccines TARGET | hepatitis B vaccines | National Heart, Lung, and Blood Institute (NHLBI) | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- hepatitis B vaccines CI watch — RSS
- hepatitis B vaccines CI watch — Atom
- hepatitis B vaccines CI watch — JSON
- hepatitis B vaccines alone — RSS
Cite this brief
Drug Landscape (2026). hepatitis B vaccines — Competitive Intelligence Brief. https://druglandscape.com/ci/hepatitis-b-vaccines. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing